림프절전이가 없는 폐경 후 유방암의 호르몬치료제로서 Tamoxifen과 Toremifene의 비교
Comparison of Tamoxifen and Toremifene as Adjuvant Treatment in Node-negative Postmenopausal Breast Cancer
한세환, 양근호, 배병노, 김기환, 김홍주, 김영덕, 김홍용,
소속 상세정보
한세환 ( Han Se-Hwan )
인제대학교 의과대학 상계백병원 외과학교실
양근호 ( Yang Keun-Ho )
인제대학교 의과대학 상계백병원 외과학교실
배병노 ( Bae Byung-Noe )
인제대학교 의과대학 상계백병원 외과학교실
김기환 ( Kim Ki-Whan )
인제대학교 의과대학 상계백병원 외과학교실
김홍주 ( Kim Hong-Joo )
인제대학교 의과대학 상계백병원 외과학교실
김영덕 ( Kim Young-Duck )
인제대학교 의과대학 상계백병원 외과학교실
김홍용 ( Kim Hong-Yong )
인제대학교 의과대학 상계백병원 외과학교실
KMID : 0371320020630040283
Abstract
Purpose: To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifene in postmenopausal breast cancer patients.
Methods: Toremifene 40 ㎎ (n=115) and tamoxifen 20 ㎎ (n =116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the
patient
survival rate was also analyzed.
Results: Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen= 47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following
adverse
effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range: 9∼38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively,
had
recurrent disease.
Conclusion: The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 ㎎/day seems to be as safe and effective as tamoxifen at 20 ㎎/day in the treatment of postmenopausal,
node-negative,
breast cancer. However, a longer follow-up study is needed to verify this.
키워드
부작용; 유방암; 치료; Tamoxifen; Toremifen; Breast cancer; Side effect; Tamoxifen; Toremifene; Treatment;
원문 및 링크아웃 정보
등재저널 정보